Catalog No.	C043P
Product Name	Daclizumab Biosimilar, Anti-human CD25 Antibody | C043P
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	Interleukin-2 receptor alpha chain, CD25, IL2RA, IDDM10, IL2R, TCGFR, p55, IMD41, interleukin 2 receptor subunit alpha
Summary	Recombinant Humanized IgG1 Monoclonal Antibody.
Source/Host	The anti-human CD25 monoclonal antibody daclizumab biosimilar was produced in the daclizumab biosimilar CHO stable cell line.
Specificity/Sensitivity	The in vivo grade daclizumab biosimilar specifically binds to the human interleukin-2 receptor (anti-Tac or anti-CD25).
Applications	ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by daclizumab.
Form Of Antibody	0.2 uM filtered solution, pH 6.0, no stabilizers or preservatives.
Endotoxin	<1 EU/mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The research grade daclizumab biosimilar is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	The research grade Daclizumab biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card.

Description

C042P

C043P: Daclizumab Biosimilar, Anti-human CD25 Monoclonal Antibody

Recombinant Humanized IgG1 Monoclonal Antibody.

Background

Daclizumab Biosimilar uses the same protein sequences as the therapeutic antibody daclizumab.

Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.

Daclizumab binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.

Daclizumab Biosimilar from: Daclizumab Biosimilar, CD25 Monoclonal Antibody: C043P Syd Labs

No more offers for this product!